U.S. Markets close in 2 hrs 20 mins

Halozyme Therapeutics Inc. Regi (RV7.SG)


Stuttgart - Stuttgart Delayed Price. Currency in EUR
Add to watchlist
13.04+0.11 (+0.88%)
As of 4:13PM CEST. Market open.
Full screen
Previous Close12.93
Open13.05
Bid13.03 x 250000
Ask13.39 x 500000
Day's Range13.04 - 13.59
52 Week Range6.91 - 13.69
Volume200
Avg. Volume41
Market CapN/A
BetaN/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Accesswire6 hours ago

    Halozyme FDA Action Date, Q1 Review, Analysts Outlook and Price Targets

    NEW YORK, NY / ACCESSWIRE / June 26, 2017 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies is issuing a comprehensive ...

  • FDA Approves Genentech's RITUXAN HYCELA, A Subcutaneous Rituximab Coformulated With Halozyme ENHANZE Technology
    PR Newswire4 days ago

    FDA Approves Genentech's RITUXAN HYCELA, A Subcutaneous Rituximab Coformulated With Halozyme ENHANZE Technology

    SAN DIEGO , June 22, 2017 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies, today announced that the U.S. Food and ...

  • Halozyme Phase 2 Data In Advanced Pancreas Cancer Featured In An Oral Presentation At ASCO
    PR Newswire22 days ago

    Halozyme Phase 2 Data In Advanced Pancreas Cancer Featured In An Oral Presentation At ASCO

    CHICAGO, June 4, 2017 /PRNewswire/ -- Encouraging results from a Phase 2 randomized, multi-center clinical trial in pancreas cancer patients conducted by Halozyme Therapeutics (HALO) were presented today at the American Society of Clinical Oncology (ASCO) annual conference. Principal Investigator Sunil R. Hingorani, M.D., Ph.D., a pancreas cancer expert at Fred Hutchinson Cancer Research Center and professor at University of Washington School of Medicine expanded on findings from patient data as of December 2016 in the HALO-202 study of investigational new drug, PEGPH20 (pegvorhyaluronidase alpha) in combination with ABRAXANE® (nab-paclitaxel) and gemcitabine. PEGPH20 plus standard chemotherapy of ABRAXANE and gemcitabine improved median PFS by 77 percent over chemotherapy alone in HA-High patients.